title: [Plant-derived terpenes in treating patients with urolithiasis].
abstract: Numerous metabolic abnormalities intrinsic to urolithiasis require drug therapy. At the same time, despite the constant expansion of synthetic drugs, plant-derived medications play a large role in the treatment and prevention of the disease.
  
  
  OBJECTIVE
  To evaluate the effect of a plant-derived preparation Rowatinex in patients with urolithiasis after extracorporeal shock wave lithotripsy (ESWL) and analyze the changes in blood and urine parameters in patients receiving the preparation.
  
  
  METHODS
  Depending on the type of post-ESWL treatment, patients were divided into two groups. After ESWL, patients of group A (n=107) and group B (n=50) were administered Rowatinex and antispasmodic drugs, respectively.
  
  
  CONCLUSIONS
  Clearance of stone fragments after ESWL within 1-5 days was achieved in 76 (71.1%) patients of group A and in 20 (40.4%) of group B. Analysis of the effect of the therapy on blood count, biochemistry tests and 24h excretion (magnesium, uric acid, calcium, etc.) did not reveal significant differences between group A group B and reference values. Increased diuresis caused by antispasmodic effects of Rowatinex resulted in the complete clearance of stone fragments. Urinalysis in patients of the two groups showed decreased leukocyturia. Furthermore, stabilization of urine pH within the 6.2-6.8 was noted in group A, which is important and necessary in metaphylaxis of recurrent stone formation.
  
  
  CONCLUSIONS
  Administration of Rowatinex increases the percentage of stone fragment clearance after ESWL and reduces pain intensity. Rowatinex reduces leukocyturia, increases 24h diuresis and stabilizes the pH of urine. Increasing and stabilizing urine pH in patients with calcium oxalate and urate stones reduces the risk of recurrence after ESWL. No complications associated with Rowatinex were reported, allowing long-term administration of the preparation in the complex lithokinetic therapy and for metaphylaxis of recurrent stone formation.
authors.affiliation: Department of Urology, Sechenov First Moscow State Medical University, Moscow.
authors.forename: Yu G
authors.initials: YG
authors.lastname: Alyaev
authors.affiliation: Department of Urology, Sechenov First Moscow State Medical University, Moscow.
authors.forename: V I
authors.initials: VI
authors.lastname: Rudenko
authors.affiliation: Department of Urology, Sechenov First Moscow State Medical University, Moscow.
authors.forename: A N
authors.initials: AN
authors.lastname: Perekalina
authors.affiliation: Department of Urology, Sechenov First Moscow State Medical University, Moscow.
authors.forename: I G
authors.initials: IG
authors.lastname: Kraev
authors.affiliation: Department of Urology, Sechenov First Moscow State Medical University, Moscow.
authors.forename: Zh Sh
authors.initials: ZS
authors.lastname: Inoyatov
mesh_terms: D005260:Female; D006801:Humans; D008096:Lithotripsy; D008297:Male; D028321:Plant Preparations / Q000008:administration & dosage*; D013729:Terpenes / Q000008:administration & dosage*; D052878:Urolithiasis / Q000628:therapy* / Q000652:urine
chemical_list: D028321:Plant Preparations; D013729:Terpenes; C036965:Rowatinex
keywords: Rovatineks; extracorporeal shock wave lithotripsy; phytotherapy; terpenes; urolithiasis